Collegium Pharmaceutical, Inc. (COLL)

Market Cap	713.94M -33.0%
Revenue (ttm)	808.21M +14.3%
Net Income	47.92M +32.1%
EPS	1.41 +32.7%
Shares Out	32.56M
PE Ratio	15.87
Forward PE	3.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,385
Open	22.03
Previous Close	21.93
Day's Range	21.80 - 22.03
52-Week Range	21.43 - 50.79
Beta	0.73
Analysts	Buy
Price Target	49.00 (+123.44%)
Est. Earnings	Nov 5, 2026

About COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxyco...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 7, 2015
• Employees: 423
• Stock Exchange: Nasdaq
• Ticker Symbol: COLL
• Website: https://www.collegiumpharma.com

Financial Performance

In 2025, Collegium Pharmaceutical's revenue was $780.57 million, an increase of 23.62% compared to the previous year's $631.45 million. Earnings were $62.87 million, a decrease of -9.13%.

Analyst Summary

According to 8 analysts, the average rating for COLL stock is "Buy." The 12-month stock price target is $49.0, which is an increase of 123.44% from the latest price.

Price Target

$49.0

(123.44% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 8, 2026

Data Sources Report a data error